Australia markets closed

Mereo BioPharma Group plc (MREO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.9800+0.0900 (+2.31%)
At close: 04:00PM EDT
4.0993 +0.12 (+3.00%)
Pre-market: 08:38AM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
-26,341
-29,466
-42,220
17,174
-222,996
-
Depreciation & amortisation
1,109
1,061
889
866.4669
2,179
-
Stock-based compensation
5,339
4,924
4,768
4,457
2,123
-
Change in working capital
-3,470
-1,593
-2,352
-2,490
-4,647
-
Other working capital
-20,575
-21,551
-48,834
-7,793
-38,646
-
Other non-cash items
2,216
1,840
2,103
18,097
7,121
-
Net cash provided by operating activities
-19,875
-21,132
-48,821
-7,071
-38,624
-
Cash flows from investing activities
Investments in property, plant and equipment
-700
-419
-13
-722.0558
-21.8052
-
Acquisitions, net
-
-
0
0
-482.44
0
Sales/maturities of investments
-
-
-
0
0
43,091
Other investing activities
-
-
-814.4643
-
-
-
Net cash used for investing activities
-700
-419
1,987
-568.1972
2,037
-
Cash flows from financing activities
Debt repayment
-
-3,188
-1,134
-933.9488
-29,830
-
Common stock issued
-
11,605
0
105,990
27,442
-
Common stock repurchased
-
-
-
0
0
-1,309
Dividends paid
-
-
0
0
0
0
Other financing activities
-
-444
200
-315.815
-6,795
-
Net cash used provided by (used for) financing activities
-
7,973
200
104,802
47,340
-
Net change in cash
-12,603
-13,579
-46,634
97,163
10,754
-
Cash at beginning of period
59,808
68,182
127,398
31,675
22,278
-
Cash at end of period
47,205
57,421
68,182
127,265
31,984
-
Free cash flow
Operating cash flow
-19,875
-21,132
-48,821
-7,071
-38,624
-
Capital expenditure
-700
-419
-13
-722.0558
-21.8052
-
Free cash flow
-20,575
-21,551
-48,834
-7,793
-38,646
-